A Analgesic Study of Adductor Canal &IPACK Block With Liposomal Bupivacaine in Knee Arthroplasty

Sponsor
Nanjing First Hospital, Nanjing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06145165
Collaborator
(none)
90
1
3
13
6.9

Study Details

Study Description

Brief Summary

To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty

Condition or Disease Intervention/Treatment Phase
  • Other: Nerve block with ropivacaine and intravenous analgesia
  • Combination Product: Nerve block with liposomal bupivacaine and intravenous analgesia
  • Other: Intravenous analgesia
Phase 1

Detailed Description

The pain after knee arthroplasty limits the patient's activities and postoperative recovery, and currently there are mainly three analgesic methods: intravenous analgesia, epidural analgesia and nerve block analgesia. There is a lack of studies on whether liposomal bupivacaine, if used for ACB and iPACK block, can achieve benefits in knee arthroplasty pain management by prolonging sensory nerve block without affecting muscle strength, improving patient prognosis, and shortening hospitalization days.

In this study, in order to better evaluate the effect of liposomal bupivacaine for ACB and iPACK biock on the prognosis of patients undergoing knee arthroplasty, not only the NRS and AUC of patients in each group will be observed, but also the postoperative QoR-15 Quality of Recovery Rating Scale, postoperative nausea, vomiting and other complications, and the number of hospitalization days will be also included as observation indicators. The completion of this study can provide a clinical basis for the selection of analgesic regimens for knee arthroplasty, and also provide strong evidence-based medical support for the relevant medical decision making of government departments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
A Analgesic Study of Adductor Canal &IPACK Block With Liposomal Bupivacaine in Knee Arthroplasty :A Randomized,Double-controlled,Parallel-controlled,Single-center Study
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: RP group:Nerve block with ropivacaine and intravenous analgesia group

The ropivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia

Other: Nerve block with ropivacaine and intravenous analgesia
When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Experimental: LP group :Nerve block with liposomal bupivacaine and intravenous analgesia group

The liposomal bupivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia

Combination Product: Nerve block with liposomal bupivacaine and intravenous analgesia
When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Placebo Comparator: control group:Intravenous analgesia group

General anesthesia was induced directly

Other: Intravenous analgesia
When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Outcome Measures

Primary Outcome Measures

  1. The cumulative use of analgesic drugs (sufentanil,calculated in ug)up to 48 hours postoperative in each group [Up to 48 hours postoperative]

    To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty.A lower dose of analgesics indicates a longer duration of block.

Secondary Outcome Measures

  1. NRS scores at rest and during exerciseat at 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours postoperative [at 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours postoperative]

    The NRS typically consists of a straight line with numbers ranging from 0 to 10. Each number corresponds to a level of pain intensity:0: No pain.1 to 3: Mild pain (low intensity). 4 to 6: Moderate pain (moderate intensity). 7 to 10: Severe pain (high intensity) Patients are asked to choose a number that best represents their current pain level, where 0 means no pain, and 10 indicates the worst possible pain.A lower NRS score indicates a longer duration of block.

  2. The total number of PCIA compressions on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Fewer total PCIA compressions indicated a longer duration of block.

  3. The number of effective PCIA compressions on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Fewer total effective PCIA compressions indicated a longer duration of block.

  4. The number of times of remedial analgesia on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Fewer times of rescue analgesia indicated a longer duration of analgesia.

  5. The cumulative use of analgesic drugs (sufentanil,calculated in ug)on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Less cumulative use of analgesics indicates a longer duration of block

  6. The percentage of subjects who did not use remedial analgesics on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    A greater percentage of subjects who did not use rescue analgesics indicated a longer duration of analgesic block.

  7. Satisfaction score of subjects on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Rated on a 0-10 scale, with a higher score representing greater satisfaction.

  8. Satisfaction score of surgeons on the first day,the second day and the third day after surgery. [On the first day,the second day and the third day after surgery.]

    Rated on a 0-10 scale, with a higher score representing greater satisfaction.

  9. Both the liposomal bupivacaine group and the ropivacaine group were subjected to ACB and iPACK block. PI-AUC72 was observed in the three groups [within 72 hours after the first postoperative initiation of drug administration]

    A smaller PI-AUC72 indicates a longer duration of nerve block.

  10. 15-item Quality of Recovery Rating Scale (QoR-15): 24h, 48h and 72h postoperatively [at 24 hours, 48 hours and 72 hours postoperative]

    QoR-15 was used to assess five aspects of postoperative recovery quality (physical comfort, physical independence, psychological support, emotion and pain), with higher scores indicating the higher postoperative recovery quality. The lowest score is 0 points, and the highest score is 150 points.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age 18-79 years.

  2. Patients undergoing unilateral total knee arthroplasty or unicondylar joint replacement.

  3. Normal diet.

  4. ASA grade I~Ⅲ;

  5. BMI 18-30kg /m2.

  6. No intraspinal anesthesia contraindications.

Exclusion Criteria:
  1. Patients with severe neurological diseases.

  2. Hearing and speech impaired.

  3. Preoperative gastric emptying disorders, such as gastrointestinal obstruction, gastroesophageal reflux, or previous gastrointestinal surgery, etc.

  4. Patients with severe renal insufficiency or other severe metabolic diseases.

  5. Mental disorders, alcoholism or a history of drug abuse.

  6. The surgical time is greater than 3 hours.

  7. Puncture site infection, abnormal coagulation function, and local anesthetic allergy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nanjing First Hospital Nanjing Jiangsu China 210006

Sponsors and Collaborators

  • Nanjing First Hospital, Nanjing Medical University

Investigators

  • Study Chair: Liu Han, Nanjing First Hospital, Nanjing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nanjing First Hospital, Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT06145165
Other Study ID Numbers:
  • KY20230829-05
First Posted:
Nov 24, 2023
Last Update Posted:
Nov 24, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2023